[1] E D Thomas, H L Lochte, W C Lu et al. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. The New England Journal of Medicine, 257, 491-496(1957).

[2] F Khimani, M Dutta, R Faramand et al. Impact of total body irradiation-based myeloablative conditioning regimens in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: systematic review and meta-analysis. Transplantation and Cellular Therapy, 27, 620.e1-620620.e9(2021).

[3] S Giebel, M Labopin, M Sobczyk-Kruszelnicka et al. Total body irradiation + fludarabine compared to busulfan + fludarabine as“reduced-toxicity conditioning”for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplantation, 56, 481-491(2021).

[4] H J Deeg, B M Sandmaier. Who is fit for allogeneic transplantation?. Blood, 116, 4762-4770(2010).

[5] S L Wolden, R A Rabinovitch, N H J Bittner et al. American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) practice guideline for the performance of total body irradiation (TBI). American Journal of Clinical Oncology, 36, 97-101(2013).

[6] M Sabloff, S Chhabra, T Wang et al. Comparison of high doses of total body irradiation in myeloablative conditioning before hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation, 25, 2398-2407(2019).

[7] R Gopal, C S Ha, S L Tucker et al. Comparison of two total body irradiation fractionation regimens with respect to acute and late pulmonary toxicity. Cancer, 92, 1949-1958(2001).

[8] H Y Zhang, Z P Fan, F Huang et al. Busulfan plus cyclophosphamide versus total body irradiation plus cyclophosphamide for adults acute B lymphoblastic leukemia: an open-label, multicenter, phase III trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 41, 343-353(2023).

[9] J Y C Wong, A R Filippi, B S Dabaja et al. Total body irradiation: guidelines from the international lymphoma radiation oncology group (ILROG). International Journal of Radiation Oncology, 101, 521-529(2018).

[10] N Ishibashi, T Soejima, H Kawaguchi et al. National survey of myeloablative total body irradiation prior to hematopoietic stem cell transplantation in Japan: survey of the Japanese Radiation Oncology Study Group (JROSG). Journal of Radiation Research, 59, 477-483(2018).

[11] A Gruen, S Exner, J S Kühl et al. Total body irradiation as part of conditioning regimens in childhood leukemia—long-term outcome, toxicity, and secondary malignancies. Strahlentherapie Und Onkologie, 198, 33-38(2022).

[12] X H Zhang, J Chen, M Z Han et al. The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. Journal of Hematology & Oncology, 14, 145(2021).

[13] B P Quaranta, E C Halperin, J Kurtzberg et al. The incidence of testicular recurrence in boys with acute leukemia treated with total body and testicular irradiation and stem cell transplantation. Cancer, 101, 845-850(2004).

[14] J M Famoso, J L Grow, B Laughlin et al. The impact of low-dose cranial boost on the long-term outcomes of adult patients with high-risk acute lymphoblastic leukemia undergoing total body irradiation and allogeneic hematopoietic stem cell transplantation. Practical Radiation Oncology, 9, e283-e289(2019).

[15] R W Gao, K E Dusenbery, Q Cao et al. Augmenting total body irradiation with a cranial boost before stem cell transplantation protects against post-transplant central nervous system relapse in acute lymphoblastic leukemia. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation, 24, 501-506(2018).

[16] S R Pingali, R E Champlin. Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation. Bone Marrow Transplantation, 50, 1157-1167(2015).

[17] U Hegenbart, D Niederwieser, B M Sandmaier et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 24, 444-453(2006).

[18] O Ringdén, M Labopin, G Ehninger et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 27, 4570-4577(2009).

[19] M de Lima, D Couriel, P F Thall et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood, 104, 857-864(2004).

[20] J Aoki, S Seo, H Kanamori et al. Impact of low-dose TBI on outcomes of reduced intensity conditioning allogeneic hematopoietic stem cell transplantation for AML. Bone Marrow Transplantation, 51, 604-606(2016).

[21] M Tomblyn, C Brunstein, L J Burns et al. Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation, 14, 538-545(2008).

[22] S Sampath, T E Schultheiss, J Wong. Dose response and factors related to interstitial pneumonitis after bone marrow transplant. International Journal of Radiation Oncology, 63, 876-884(2005).

[23] C I Chen, R Abraham, R Tsang et al. Radiation-associated pneumonitis following autologous stem cell transplantation: predictive factors, disease characteristics and treatment outcomes. Bone Marrow Transplantation, 27, 177-182(2001).

[24] T J Keane, J Van Dyk, W D Rider. Idiopathic interstitial pneumonia following bone marrow transplantation: the relationship with total body irradiation. International Journal of Radiation Oncology, 7, 1365-1370(1981).

[25] J Vogel, S Hui, C H Hua et al. Pulmonary toxicity after total body irradiation ― critical review of the literature and recommendations for toxicity reporting. Frontiers in Oncology, 11, 708906(2021).

[26] R W Gao, D J Weisdorf, T E DeFor et al. Influence of total body irradiation dose rate on idiopathic pneumonia syndrome in acute leukemia patients undergoing allogeneic hematopoietic cell transplantation. International Journal of Radiation Oncology, 103, 180-189(2019).

[27] E Durie, E Nicholson, C Anthias et al. Determining the incidence of interstitial pneumonitis and chronic kidney disease following full intensity haemopoetic stem cell transplant conditioned using a forward-planned intensity modulated total body irradiation technique. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology, 158, 97-103(2021).

[28] K S Baker, W M Leisenring, P J Goodman et al. Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation. Blood, 133, 2790-2799(2019).

[29] H B Kal, M L VAN Kempen-Harteveld. Induction of severe cataract and late renal dysfunction following total body irradiation: dose-effect relationships. Anticancer Research, 29, 3305-3309(2009).

[30] B Q Guo, C Sheen, E Murphy et al. Image-guided volumetric-modulated arc therapy of total body irradiation: an efficient workflow from simulation to delivery. Journal of Applied Clinical Medical Physics, 22, 169-177(2021).

[31] N Kovalchuk, E Simiele, L Skinner et al. The stanford volumetric modulated arc therapy total body irradiation technique. Practical Radiation Oncology, 12, 245-258(2022).

[32] C Marquez, C Hui, E Simiele et al. Volumetric modulated arc therapy total body irradiation in pediatric and adolescent/young adult patients undergoing stem cell transplantation: early outcomes and toxicities. Pediatric Blood & Cancer, 69, e29689(2022).

[33] T Uehara, H Monzen, M Tamura et al. Feasibility study of volumetric modulated arc therapy with Halcyon™ linac for total body irradiation. Radiation Oncology, 16, 236(2021).

[34] E R Zhang-Velten, D Parsons, P Lee et al. Volumetric modulated arc therapy enabled total body irradiation (VMAT-TBI): six-year clinical experience and treatment outcomes. Transplantation and Cellular Therapy, 28, 113.e1-113.e8(2022).

[35] T Shahid, S Mandal, S S Biswal et al. Preclinical validation and treatment of volumetric modulated arc therapy based total bone marrow irradiation in Halcyon™ ring gantry linear accelerator. Radiation Oncology, 17, 145(2022).

[36] L Shi, X Lu, D Deng et al. The safety and efficacy of a novel hypo-fractionated total marrow and lymphoid irradiation before allogeneic stem cell transplantation for lymphoma and acute leukemia. Clinical and Translational Radiation Oncology, 26, 42-46(2021).

[37] C H Han, A Liu, J Y C Wong. Target coverage and normal organ sparing in dose-escalated total marrow and lymphatic irradiation: a single-institution experience. Frontiers in Oncology, 12, 946725(2022).

[38] F Y Kong, S P Liu, L L Liu et al. Clinical study of total bone marrow combined with total lymphatic irradiation pretreatment based on tomotherapy in hematopoietic stem cell transplantation of acute leukemia. Frontiers in Oncology, 12, 936985(2022).

[39] A A Loginova, D A Tovmasian, A O Lisovskaya et al. Optimized conformal total body irradiation methods with helical tomotherapy and elekta VMAT: implementation, imaging, planning and dose delivery for Pediatric patients. Frontiers in Oncology, 12, 785917(2022).

[40] Zhiwei CHEN. Three-degree-of-freedom precision counterpoint for total body irradiation.

[41] Zhiwei CHEN. A two-dimensional movable lung lead shield for radiotherapy.

[42] Yi XU, Yong LIU, Shengyu YAO et al. A fixation device for total body irradiation.

[43] Zhiwei CHEN. A water tank with adjustable thickness.

[44] Yong LIU, Xuming CHEN, Shengyu YAO et al. An equipment for total body irradiation.

[45] Yong LIU, Xuming CHEN, Shengyu YAO et al. A lung protective screen for total body irradiation.

[46] Xuming CHEN, Shengyu YAO, Yi XU et al. Application of MOSFET detector in the quality control of total body irradiation. China Medical Devices, 29, 117-118(2014).

[47] J V Dyk, J M Galvin, G P Glasgow et al. The physical aspects of total and half body photon irradiation(1986).

[48] Yimin HU, Hongzhi ZHANG, Jianrong DAI. Physics of Radiation Oncology(1999).

[49] E J Bloemen-van Gurp, B J Mijnheer, T A M Verschueren et al. Total body irradiation, toward optimal individual delivery: dose evaluation with metal oxide field effect transistors, thermoluminescence detectors, and a treatment planning system. International Journal of Radiation Oncology, 69, 1297-1304(2007).

[50] C C Pinnix, G L Smith, S Milgrom et al. Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma. International Journal of Radiation Oncology, 92, 175-182(2015).

[51] Jie HE, Lühua WANG, Yexiong LI et al. Basic guidelines of quality control for radiotherapy. Chinese Journal of Radiation Oncology, 27, 335-342(2018).

[52] B Tas, I F Durmus, A Okumus et al. Total-body irradiation using linac-based volumetric modulated arc therapy: its clinical accuracy, feasibility and reliability. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology, 129, 527-533(2018).

[53] A Springer, J Hammer, E Winkler et al. Total body irradiation with volumetric modulated arc therapy: Dosimetric data and first clinical experience. Radiation Oncology, 11, 46(2016).

[54] K Symons, C Morrison, J Parry et al. Volumetric modulated arc therapy for total body irradiation: a feasibility study using Pinnacle3 treatment planning system and Elekta Agility™ linac. Journal of Applied Clinical Medical Physics, 19, 103-110(2018).

[55] J P Cleuziou, C Desgranges, I Henry et al. Total body irradiation using helical tomotherapy: set-up experience and in-vivo dosimetric evaluation. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 25, 213-221(2021).

[56] K Dibs, A J Sim, J A Peñagaricano et al. Gonadal-sparing total body irradiation with the use of helical tomotherapy for nonmalignant indications. Reports of Practical Oncology and Radiotherapy: Journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 26, 153-158(2021).

[57] Zhengxin GAO, Qiuyi XU, Fei GONG et al. Total-body CT simulation and image reconstruction method for total-body irradiation. Chinese Journal of Medical Physics, 40, 286-290(2023).

[58] Shen FU, Zuofeng LI, Jiayi CHEN et al. Practical guideline for total body irradiation: NCC/T-RT 011―2023(2023).

[59] R C Larson, M V Maus. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nature Reviews Cancer, 21, 145-161(2021).